Dr. Reddy's Laboratories reported revenues of $39.2 million from its fluoxetine product in the fiscal year 2001 [1]. This revenue contributed to the company's overall growth during that period.
How did fluoxetine perform in Dr. Reddy's portfolio?
Fluoxetine was a significant product for Dr. Reddy's, marking its entry into the U.S. market and contributing to its financial results in fiscal year 2001.
What was the regulatory status of fluoxetine around 2001?
In the early 2000s, fluoxetine, widely known by the brand name Prozac, was an established antidepressant. Companies like Dr. Reddy's were often launching generic versions of such medications as patents expired, leading to increased competition and market access [2].
What other products did Dr. Reddy's offer in 2001?
Beyond fluoxetine, Dr. Reddy's portfolio in 2001 included a range of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and proprietary products. The company was actively expanding its global presence, particularly in regulated markets like the United States [1].
What were the key markets for Dr. Reddy's in 2001?
The United States was a crucial market for Dr. Reddy's in 2001, with the company focusing on expanding its generic drug offerings. India and other emerging markets also represented significant revenue streams [1].
When did Dr. Reddy's launch its fluoxetine product?
Dr. Reddy's launched its fluoxetine product in the U.S. market in the fiscal year 2001 [1].
What was the market for fluoxetine like in 2001?
The market for fluoxetine in 2001 included both the branded product (Prozac) and generic alternatives. The presence of generic versions typically led to price competition.
How did Dr. Reddy's revenue from fluoxetine compare to its total revenue in 2001?
In fiscal year 2001, Dr. Reddy's total revenue was $302.2 million. The $39.2 million from fluoxetine represented a substantial portion of this total, indicating its importance to the company's financial performance [1].
What were Dr. Reddy's expansion strategies around 2001?
Around 2001, Dr. Reddy's was pursuing a strategy of expanding its generic pharmaceutical offerings in developed markets, alongside growing its API business and proprietary product portfolio. This included obtaining regulatory approvals and building market share in regions like the U.S. and Europe [1].
What are Dr. Reddy's current revenue figures for fluoxetine?
Information on Dr. Reddy's current specific revenue figures for fluoxetine is not provided in the context of the 2001 data.
---
Sources:
1. https://www.drreddys.com/media/160709/dr-reddys-laboratories-limited-annual-report-2000-01.pdf
2. https://www.fda.gov/drugs/generic-drugs/what-generic-drug-generic-drugs-are-safe-and-effective-and-how-fda-ensures-their-quality